Sanofi's Dual-Target Bispecific Lunsekimig Shows Promise in Phase 2 Respiratory Disease Studies
核心洞察
Sanofi's lunsekimig, a novel bispecific Nanobody targeting TSLP (搜索) and IL-13 (搜索), met primary and key secondary endpoints in phase 2 studies for moderate-to-severe asthma (搜索) and chronic rhinosinusitis with nasal polyps (搜索).
The AIRCULES phase 2b study demonstrated statistically significant and clinically meaningful reduction in asthma (搜索) exacerbations and improvement in lung function regardless of biomarker status.
The DUET phase 2a study achieved its primary endpoint of nasal polyp score improvement and key secondary endpoints including nasal congestion scores in CRSwNP patients.
Sanofi announced positive results from two phase 2 studies of lunsekimig, a novel bispecific Nanobody designed to simultaneously target TSLP (搜索) and IL-13 (搜索), key inflammatory pathways in respiratory diseases. The dual-targeting approach demonstrated efficacy in moderate-to-severe asthma (搜索) and chronic rhinosinusitis with nasal polyps (搜索) (CRSwNP), positioning the drug as a potential breakthrough treatment for patients with poorly controlled respiratory conditions.
Promising Results in Asthma Treatment
The AIRCULES phase 2b study (NCT06102005) enrolled adult patients with moderate-to-severe asthma (搜索) and achieved its primary endpoint of reducing annualized asthma exacerbation rates over 48 weeks. The study demonstrated statistically significant and clinically meaningful improvements regardless of biomarker status, including fractional exhaled nitric oxide (FeNO) and eosinophil values.
"These data are promising and support our belief that the dual-targeting mechanism of lunsekimig may offer a novel treatment option for patients living with respiratory diseases, including asthma (搜索)," said Houman Ashrafian, Executive Vice President, Head of Research & Development at Sanofi.
The study also met its key secondary endpoint, showing improvement in lung function as measured by pre-bronchodilator forced expiratory volume in one second (pre-BD FEV1) at Week 48. This represents a significant advancement for patients with moderate-to-severe asthma (搜索), a condition marked by recurrent symptoms and frequent flareups despite standard-of-care treatment.
Success in Nasal Polyp Treatment
The DUET phase 2a proof-of-concept study (NCT06454240) evaluated lunsekimig in patients with CRSwNP, a persistent inflammatory disease characterized by soft, noncancerous growths in nasal passages. The study met its primary endpoint of change in nasal polyp score from baseline at Week 24 through bilateral endoscopy.
Key secondary endpoints were also achieved, including improvements in patient-reported nasal congestion/obstruction scores and Lund-Mackay Computed Tomography (LMK-CT) scores, all compared to placebo. These results reinforce lunsekimig's potential as a respiratory treatment, particularly given that the majority of CRSwNP patients have comorbid asthma (搜索).
Novel Dual-Target Mechanism
Lunsekimig represents a unique therapeutic approach as a pentavalent Nanobody VHH composed of five linked antibody fragments. The drug simultaneously blocks TSLP (搜索), an upstream initiator of inflammation, and IL-13 (搜索), a downstream cytokine causing tissue organ damage in respiratory diseases. This dual mechanism also includes albumin binding for extended half-life.
Pre-clinical research suggests that targeting these pathways simultaneously can potentially lead to additive and synergistic benefits in immune-mediated diseases such as asthma (搜索), addressing the significant unmet need in respiratory disease management.
Safety Profile and Tolerability
Across both respiratory studies, lunsekimig demonstrated an acceptable safety profile. In the AIRCULES study, the most common treatment-emergent adverse events (≥5%) among patients receiving lunsekimig were nasopharyngitis, upper respiratory tract infection, headache, and dose scheduling errors.
In the DUET study, common adverse events included injection site reaction or erythema, viral upper respiratory tract infection, nasopharyngitis, epistaxis, ear pain, and increased creatine phosphokinase. Importantly, rates of serious adverse events and treatment discontinuations were similar between lunsekimig and placebo groups in both studies.
Mixed Results in Dermatology
While respiratory applications showed promise, the exploratory VELVET phase 2b study (NCT06790121) in moderate-to-severe atopic dermatitis (搜索) did not meet its primary endpoint of percent change from baseline in eczema area severity index (EASI) score. However, improvements were observed in key secondary endpoints measuring skin clearance, including EASI-75 and validated investigator global assessment scores.
Addressing Significant Medical Need
The positive respiratory results address a substantial unmet medical need. Asthma (搜索) affects an estimated 262 million patients globally as of 2019, with more than 50% having poorly controlled disease despite available therapies. The persistent need for treatments that prevent and reduce asthma exacerbations represents a significant opportunity, as these events profoundly diminish patients' quality of life and contribute substantially to healthcare resource utilization.
Clinical Development Pipeline
Lunsekimig is currently advancing through an extensive clinical development program. The drug is being evaluated in the AIRLYMPUS phase 2 study for high-risk asthma (搜索) (NCT06676319) and has progressed to phase 3 trials with the PERSEPHONE (NCT07190209) and THESEUS (NCT07190222) studies.
Detailed results from the AIRCULES, DUET, and VELVET studies will be presented at upcoming medical congresses, providing the scientific community with comprehensive data on this novel dual-targeting approach to respiratory disease treatment.